Kazlauskas Vytis, Bilius Vytautas, Jakutis Virginijus, Komiagiene Renata, Burnyte Birute, Verkauskas Gilvydas
Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Clinic of Anesthesiology and Intensive Care, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Front Pediatr. 2022 Jan 6;9:762417. doi: 10.3389/fped.2021.762417. eCollection 2021.
To establish the efficacy of ultrasound (US) combined with urine biomarkers in differentiating patients who require surgical management from those who do not, avoiding invasive investigations. From February 2019 to February 2021, all pediatric patients who presented with hydronephrosis were selected for the study. All renal units (RU) were evaluated by US, and fresh frozen voided urine samples were collected at the time of inclusion. Hydronephrosis grade was evaluated by the Society for Fetal Urology (SFU) and an alternative grading system (AGS). Patients who had high-grade hydronephrosis on US were referred to renal scan (RS) or intervention, when there was an increase of dilatation in subsequent follow-up images. Fresh frozen urine from the control group with no history of renal diseases and no renal anomalies on US was collected. We compared differences of US parameters combined with urine biomarkers between surgically and non-surgically managed patients and between the groups of patients when they were stratified by different RS findings and analyzed whether urinary biomarkers give any additional value to US. Instead of the anterior-posterior diameter (APD), we used its ratio with mid-parenchymal thickness. The additional efficacy of biomarkers to US was calculated when the US component was derived to a cumulative APD/mid-parenchymal ratio. Sixty-four patients with hydronephrosis were prospectively included in the study accounting for a total of 81 patient visits and 162 RUs evaluated. A control group of 26 patients was collected. The mean age at inclusion in the hydronephrosis group was 43.7(±45.5) months, and a mean age in a control group was 61.2(±41.3) months. The cumulative APD/mid-parenchymal ratio combined with urinary albumin, β2 microglobulin (β2-M), and urinary neutrophil gelatinase-associated lipocalcin may have a better performance in the prediction of surgical intervention than the cumulative APD/mid-parenchymal ratio alone ( = 0.1). The best performance to detect the increased tissue transit time and obstructive curve on RS was demonstrated by the β2-M creatinine ratio. An increased cumulative APD/mid-parenchymal ratio with biomarkers together had a fairly good sensitivity and specificity for detection of DRF < 40%. According to our data, the APD/mid-parenchymal ratio alone has good efficacy in prediction of surgery and abnormal RS findings especially when combined with urine biomarkers.
为确定超声(US)联合尿液生物标志物在区分需要手术治疗的患者与不需要手术治疗的患者方面的有效性,避免进行侵入性检查。2019年2月至2021年2月,选取所有出现肾积水的儿科患者进行研究。所有肾单位(RU)均通过超声进行评估,并在纳入研究时收集新鲜冷冻的晨尿样本。肾积水分级采用胎儿泌尿外科学会(SFU)和一种替代分级系统(AGS)进行评估。超声显示为重度肾积水的患者,若在后续随访影像中肾盂扩张加重,则转诊进行肾扫描(RS)或干预治疗。收集来自无肾脏疾病史且超声检查无肾脏异常的对照组的新鲜冷冻尿液。我们比较了手术治疗和非手术治疗患者之间以及根据不同肾扫描结果分层的患者组之间超声参数联合尿液生物标志物的差异,并分析了尿液生物标志物是否为超声检查提供了额外价值。我们使用前后径(APD)与肾实质中部厚度的比值,而非前后径本身。当超声部分得出累积APD/肾实质中部比值时,计算生物标志物相对于超声的额外有效性。前瞻性纳入64例肾积水患者,共进行了81次患者访视,评估了162个肾单位。收集了26例患者作为对照组。肾积水组纳入时的平均年龄为43.7(±45.5)个月,对照组的平均年龄为61.2(±41.3)个月。累积APD/肾实质中部比值联合尿白蛋白、β2微球蛋白(β2-M)和尿中性粒细胞明胶酶相关脂质运载蛋白在预测手术干预方面可能比单独的累积APD/肾实质中部比值表现更好(P = 0.1)。β2-M肌酐比值在检测肾扫描上组织通过时间延长和梗阻曲线方面表现最佳。累积APD/肾实质中部比值升高并伴有生物标志物对检测滤过率(DRF)< 40%具有相当好的敏感性和特异性。根据我们的数据,单独的APD/肾实质中部比值在预测手术和异常肾扫描结果方面具有良好的有效性,尤其是与尿液生物标志物联合使用时。